Donor Leukocyte Trafficking and Damage-associated Molecular Pattern Expression During Ex Vivo Lung Perfusion.
Abstract
Background:While ex vivo lung perfusion (EVLP) has become established in lung transplantation,
the cellular processes occurring during this period are not yet fully understood.
Prior studies demonstrated that donor leukocytes (DLs) migrate from the graft into
the perfusate during EVLP, but the distribution of DLs in graft and perfusate compartments
has not been characterized. Moreover, cell death of DLs has been implicated in mediating
graft injury during EVLP, but the underlying mechanisms have not been elucidated.
We hypothesized the following: (1) there is a nonspecific migration of DLs from the
graft into perfusate and (2) cell death of DLs releases damage-associated molecular
patterns (DAMPs) that contribute to the inflammatory milieu during EVLP. Methods:EVLP
was performed on rat lungs for 3 hours (N = 6). At the end of EVLP, flow cytometry
was used to quantify the distribution of different DL cell types in both the graft
and perfusate compartments. During EVLP, the perfusate was also sampled hourly to
measure levels of DAMPs and downstream inflammatory cytokines generated during EVLP.
Results:At the conclusion of EVLP, there was a significantly higher proportion of
T and B cells present in the perfusate compartment compared with the graft compartment.
There was a time-dependent increase in extracellular DNA and tumor necrosis factor
α in the perfusate during EVLP. Conclusions:T cells and B cells are enriched in the
perfusate compartment during EVLP. Cell death of DLs contributes to an accumulation
of DAMPs during EVLP.
Type
Journal articlePermalink
https://hdl.handle.net/10161/20615Published Version (Please cite this version)
10.1097/TXD.0000000000000968Publication Info
Davis, Robert P; Yerxa, John; Gao, Qimeng; Gloria, Jared; Scheuermann, Uwe; Song,
Mingqing; ... Barbas, Andrew S (2020). Donor Leukocyte Trafficking and Damage-associated Molecular Pattern Expression During
Ex Vivo Lung Perfusion. Transplantation Direct, 6(3). pp. e532. 10.1097/TXD.0000000000000968. Retrieved from https://hdl.handle.net/10161/20615.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Andrew Serghios Barbas
Associate Professor of Surgery
Robert Patrick Davis
Affiliate
Matthew Hartwig
Professor of Surgery
Dr. Hartwig is a thoracic surgeon with a clinical focus in robotic assisted minimally
invasive thoracic surgery for the treatment of diseases of the chest. He serves as
the Surgical Director of the Esophageal Center at Duke. He is also the Director of
the Minimally Invasive Thoracic Surgery Fellowship at Duke, while providing advanced
instruction in robotic surgery to surgeons around the world. He also leads a successful
program of clinical, basic and translational research in tho
Jaewoo Lee
Assistant Professor in Surgery
William Parker
Associate Professor in Surgery
1. Transplantation: We have been studying transplantation and organ rejection now
for about 25 years. Work through the years has included extensive study of xenotransplantation
and aspiration-induced pulmonary rejection, with Jeffrey Platt, Randy Bollinger, Duane
Davis, and Shu Lin. New studies with organ preservation and Dr. Andrew Barbas are
now underway.
2. Gut immunity: Research has focused on the promicrobial aspects of the immune system.
In coll
This author no longer has a Scholars@Duke profile, so the information shown here reflects
their Duke status at the time this item was deposited.
Alphabetical list of authors with Scholars@Duke profiles.

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info